191 related articles for article (PubMed ID: 16373188)
1. Clearance of prions during plasma protein manufacture.
Burdick MD; Pifat DY; Petteway SR; Cai K
Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
[TBL] [Abstract][Full Text] [Related]
2. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
3. TSE clearance during plasma products separation process by Gradiflow(TM).
Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
[TBL] [Abstract][Full Text] [Related]
4. Current strategies to prevent transmission of prions by human plasma derivatives.
Burnouf T; Padilla A
Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
[TBL] [Abstract][Full Text] [Related]
5. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
Kozak RW; Golker CF; Stadler P
Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
[TBL] [Abstract][Full Text] [Related]
6. Atypical transmissible spongiform encephalopathies (TSEs) in ruminants.
Baron T; Biacabe AG; Arsac JN; Benestad S; Groschup MH
Vaccine; 2007 Jul; 25(30):5625-30. PubMed ID: 17126958
[TBL] [Abstract][Full Text] [Related]
7. Profiling the culprit in Alzheimer's disease (AD): bacterial toxic proteins - Will they be significant for the aetio-pathogenesis of AD and the transmissible spongiform encephalopathies?
Schmitt HP
Med Hypotheses; 2007; 69(3):596-609. PubMed ID: 17337124
[TBL] [Abstract][Full Text] [Related]
8. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
9. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
10. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
Flan B; Arrabal S
Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
[TBL] [Abstract][Full Text] [Related]
11. Insights into prion strains and neurotoxicity.
Aguzzi A; Heikenwalder M; Polymenidou M
Nat Rev Mol Cell Biol; 2007 Jul; 8(7):552-61. PubMed ID: 17585315
[TBL] [Abstract][Full Text] [Related]
12. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.
Manuelidis L
J Cell Biochem; 2007 Mar; 100(4):897-915. PubMed ID: 17044041
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of transmissible spongiform encephalopathy and methods for prion inactivation].
Papacchini M; Mansi A; Marta I
Med Lav; 2003; 94(3):271-84. PubMed ID: 12918319
[TBL] [Abstract][Full Text] [Related]
14. Partitioning of TSE infectivity during ethanol fractionation of human plasma.
Gregori L; Maring JA; MacAuley C; Dunston B; Rentsch M; Kempf C; Rohwer RG
Biologicals; 2004 Mar; 32(1):1-10. PubMed ID: 15026020
[TBL] [Abstract][Full Text] [Related]
15. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
[TBL] [Abstract][Full Text] [Related]
16. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
17. Prion agent diversity and species barrier.
Béringue V; Vilotte JL; Laude H
Vet Res; 2008; 39(4):47. PubMed ID: 18519020
[TBL] [Abstract][Full Text] [Related]
18. Removal of TSE agents by depth or membrane filtration from plasma products.
Roberts PL; Evans D; Harris L
Biologicals; 2010 Jan; 38(1):158-61. PubMed ID: 19854662
[TBL] [Abstract][Full Text] [Related]
19. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
[TBL] [Abstract][Full Text] [Related]
20. Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis.
Aguzzi A
J Neurochem; 2006 Jun; 97(6):1726-39. PubMed ID: 16805779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
